Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross SD Tarpeyo Prior Auth Update | OpenPaye…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.04.61

    Tarpeyo (budesonide delayed release) capsules

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.04.61 alerts

    Get alerted when Policy 05.04.61 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Tarpeyo capsules for members with primary immunoglobulin A nephropathy who are at risk for disease progression.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyTarpeyo (budesonide delayed release) capsules
    Policy CodePolicy 05.04.61
    Change TypeNo material change
    Effective DateMar 10, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionEnsure Tarpeyo is prescribed by or in consultation with a nephrologist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10 monthsStandard authorization duration
    ≥35Minimum eGFR
    ≥0.5 g/dayProteinuria threshold
    120 capsulesQuantity limit
    40 weeks

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum treatment duration
    NephrologistRequired specialty

    Coverage Criteria

    Initial Therapy Criteria

    Authorization of 10 months may be granted when all of the following criteria are met.

    Initial therapy approval

    • Diagnosis: Member has primary immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy
    • Age: Member is 18 years of age or older≥18 years
    • Disease progression risk: Member is at risk of rapid disease progressionProteinuria ≥0.5 g/day
    • Renal function: Member's eGFR is equal to or greater than 35 mL/min/1.73 m²≥35 mL/min/1.73 m²
    • RAS inhibitor status

      • Current RAS therapy: Member is receiving a stable dose of maximally tolerated RAS inhibitor therapy for at least 3 months and will continue RAS inhibitor therapy≥3 months

        RAS inhibitors include angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs).

      • RAS alternative: Member has an intolerance or contraindication to RAS inhibitors
    • Dose and schedule: Requested dose does not exceed the policy schedule16 mg (4 capsules) per day for 9 months, followed by 8 mg (2 capsules) per day for 2 weeks
    • Combination therapy: Requested medication will not be used in combination with Filspari (sparsentan), Vanrafia (atrasentan), Voyxact (sibeprenlimab-szsi), or Fabhalta (iptacopan)
    • Prior Tarpeyo exposure: Member has not received more than the permitted lifetime treatment duration of TarpeyoNo more than 40 weeks per lifetime

      Safety and efficacy of subsequent treatment courses beyond 40 weeks have not been established.

    Non-Formulary Exception Criteria

    A non-formulary drug may be covered when the Criteria for Approval and all of the following criteria are met.

    Non-formulary exception

    • Indication: Requested drug is used for an FDA-approved indication or an indication supported in the compendia of current literature

      Diagnostic testing or laboratory results are required when applicable.

    • Dose and quantity: Prescribed dose and quantity fall within FDA-approved labeling or dosing guidelines found in the compendia of current literature
    • Formulary alternatives: All covered formulary alternative drugs on any tier will be ineffective, have been ineffective, would not be as effective as the non-formulary drug, or would have adverse effects

      Documentation must include prior treatment failure, severity of the adverse event when applicable, dosage and duration of prior treatment, or contraindication to formulary alternatives.

    Tarpeyo must not be used in combination with Filspari (sparsentan), Vanrafia (atrasentan), Voyxact (sibeprenlimab-szsi), or Fabhalta (iptacopan).

    Tarpeyo is considered not medically necessary when the member does not meet the stated approval criteria, including the requirements for diagnosis, age, disease progression risk, renal function, RAS inhibitor status, dosing, combination therapy, and lifetime treatment duration.

    Clinical Thresholds and Limits

    Proteinuria threshold
    Minimum proteinuria≥0.5 g/day
    IndicatesRisk of rapid disease progression
    Required documentationLaboratory report and/or chart notes documenting proteinuria at or above the threshold
    Renal function threshold
    Minimum eGFR≥35 mL/min/1.73 m²
    Policy requirementThe member’s eGFR must be equal to or greater than 35 mL/min per 1.73 m²
    Applies toTarpeyo approval for primary IgA nephropathy

    Provider Requirements and Authorization Guidance

    Prior Authorization

    Nephrologist Involvement Required

    Tarpeyo must be prescribed by or in consultation with a nephrologist.

    Prior Authorization

    Authorization Duration

    Authorization may be approved for 10 months when all applicable approval criteria are met.

    Documentation Required

    Non-Formulary Use and Dosing Requirements

    For a non-formulary exception, the requested drug must be used for an FDA-approved indication or an indication supported by current literature compendia, and the prescribed dose and quantity must fall within FDA-approved labeling or compendia dosing guidelines.

    Disease Background

    Primary immunoglobulin A nephropathy (IgAN) is a kidney disease in which abnormal IgA-related immune complexes contribute to glomerular inflammation, proteinuria, and progressive loss of renal function. Tarpeyo is an oral targeted-release formulation of budesonide designed to release in the ileocecal region, where Peyer's patches may contribute to production of pathogenic galactose-deficient IgA1. The policy covers Tarpeyo for adults with primary IgAN who are at risk for disease progression, with the goal of reducing loss of kidney function.

    Policy Definitions

    Primary IgA nephropathy (IgAN)
    Disease indicationPrimary immunoglobulin A nephropathy (IgAN) in adults at risk for disease progression
    FDA-approved useTarpeyo is indicated for primary immunoglobulin A nephropathy
    Confirmation requiredDiagnosis must be confirmed by kidney biopsy
    Risk of disease progression
    DefinitionRisk of rapid disease progression is defined as proteinuria ≥0.5 g/day
    Evidence requiredLaboratory results and/or chart notes must document the proteinuria
    Coverage relevance

    Initial Therapy Criteria

    Initial Authorization

    Authorization of 10 months may be granted when all of the following criteria are met.

    Initial authorization

    • Diagnosis: Member has primary immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy
    • Age: Member is 18 years of age or older≥18 years
    • Disease progression risk: Member is at risk of rapid disease progressionProteinuria ≥0.5 g/day

    Formulary Exception Requirements

    StepRequirementSupporting documentation
    1For non-formulary coverage, all covered formulary alternatives on any tier must be ineffective, have been ineffective, would not be as effective as the requested drug, or have caused adverse effects. Formulary alternatives may also be contraindicated.Submit chart notes or other documentation showing prior treatment failure, adverse-event severity when applicable, prior dosage and duration, or contraindication to formulary alternatives.

    Quantity and Duration Limits

    Tarpeyo quantity limit
    Maximum quantity120 capsules
    Supply periodPer 30 days
    Daily equivalent4 capsules per day
    Tarpeyo duration limit
    Maximum duration40 weeks per lifetime
    Applies toAll Tarpeyo treatment received by the member over the member’s lifetime
    Further coursesSafety and efficacy of subsequent treatment courses beyond 40 weeks have not been established
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyTarpeyo (budesonide delayed release) capsules
    Policy CodePolicy 05.04.61
    Change TypeNo material change
    Effective DateMar 10, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionEnsure Tarpeyo is prescribed by or in consultation with a nephrologist.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and LimitsProvider Requirements and Authorization GuidanceDisease BackgroundPolicy DefinitionsInitial Therapy CriteriaFormulary Exception RequirementsQuantity and Duration Limits
    Tarpeyo treatment duration
    Maximum durationNo more than 40 weeks per lifetime
    Duration limit40 weeks per lifetime
    Additional treatmentSafety and efficacy of subsequent treatment courses beyond 40 weeks have not been established
    Documentation Required

    Kidney Biopsy Documentation

    Submit a kidney biopsy confirming primary immunoglobulin A nephropathy (IgAN).

    Documentation Required

    Proteinuria and Progression Risk

    Submit a laboratory report and/or chart note documenting proteinuria of at least 0.5 g/day, establishing risk of disease progression.

    Documentation Required

    Non-Formulary Exception Documentation

    If requesting a non-formulary exception, document why all covered formulary alternatives cannot be used effectively or safely. Documentation should address prior treatment failure, the severity of any adverse event, dosage and duration of prior treatment, or contraindication to the alternatives.

    Denial Risk

    Failure to Meet Approval Criteria

    Tarpeyo is not medically necessary when the member does not meet the stated approval criteria.

    Denial Risk

    Samples Do Not Bypass Authorization

    Members receiving Tarpeyo as samples or through the manufacturer's patient assistance program must still meet the criteria for initial approval. Samples or assistance do not bypass prior authorization requirements.

    Denial Risk

    Prohibited Combination Therapy

    Do not use Tarpeyo in combination with the following medications:

    • Filspari (sparsentan)
    • Vanrafia (atrasentan)
    • Voyxact (sibeprenlimab-szsi)
    • Fabhalta (iptacopan)
    The threshold is a criterion for Tarpeyo approval
    RAS inhibitor therapy
    DefinitionMaximally tolerated renin-angiotensin system (RAS) inhibitor therapy
    ExamplesAngiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs)
    Qualifying statusA stable maximally tolerated dose for at least 3 months with continued therapy planned, or an intolerance or contraindication to RAS inhibitors
    Renal function: Member's eGFR is equal to or greater than 35 mL/min/1.73 m²≥35 mL/min/1.73 m²
  1. RAS inhibitor status

    • Current RAS therapy: Member is receiving a stable dose of maximally tolerated RAS inhibitor therapy for at least 3 months and will continue RAS inhibitor therapy≥3 months

      RAS inhibitors include angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs).

    • RAS alternative: Member has an intolerance or contraindication to RAS inhibitors
  2. Dose and schedule: Requested dose does not exceed the policy schedule16 mg (4 capsules) per day for 9 months, followed by 8 mg (2 capsules) per day for 2 weeks
  3. Combination therapy: Requested medication will not be used in combination with Filspari (sparsentan), Vanrafia (atrasentan), Voyxact (sibeprenlimab-szsi), or Fabhalta (iptacopan)
  4. Prior Tarpeyo exposure: Member has not received more than the permitted lifetime treatment duration of TarpeyoNo more than 40 weeks per lifetime

    Safety and efficacy of subsequent treatment courses beyond 40 weeks have not been established.